ABX expands radiopharmaceutical production in Radeberg
The leading manufacturer of radiopharmaceuticals for cancer diagnostics and therapy - ABX advanced biochemical compounds GmbH - is planning to build a new production building.
ABX has acquired the site of the former Radeberger "Stadtentsorgung K. Nehlsen GmbH" at Pillnitzer Strasse 1-7 for the planned expansion of its company location. This was used as a glassworks until 1928. This resulted in extensive tar deposits and the entry of slag and ash to a depth of five meters. As a result, there are now pollutants in the soil.
Large-scale decontamination of the entire area is therefore necessary to ensure healthy working conditions and to remove pollutants. In addition to the demolition of old buildings, this also includes the excavation and subsequent professional disposal of the contaminated material. The site area is 2.4 hectares and is therefore the size of more than three soccer pitches.
The total costs amount to around 8.6 million euros. The State Directorate of Saxony is providing funding from the European Regional Development Fund (ERDF) and the Saxon budget amounting to around 6.6 million euros, while ABX GmbH's own contribution is 2 million euros. The funding decision was handed over on January 15, 2026.
Following the remediation work, at least 15 percent of the decontaminated area is to be renaturalized. At the same time, new production facilities will be built that are planned according to modern technical, safety and energy standards. The project thus makes an important contribution to the sustainable development of Radeberg as a business location and to strengthening regional value creation.
"With the decontamination, we are making a targeted investment in a safe, modern and sustainable business location," says Marco Müller, Managing Director of ABX. "The funding from the European Union and the German Federal State of Saxony enables us to combine economic development with ecological responsibility."